Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients

Neurol Sci. 2008 Sep:29 Suppl 2:S227-9. doi: 10.1007/s10072-008-0945-y.

Abstract

Neutralising antibodies develop in 15% of interferon-beta (IFNbeta)-treated patients, causing the reduction of the clinical effects of the treatment. This is the first study that shows that switching patients from IFNbeta to glatiramer acetate (GA) in case of neutralising antibodies (NAb) positivity is effective in reducing relapse rate and in delaying the time to first relapse. In conclusion, our data suggest the use of GA in NAb-positive patients.

MeSH terms

  • Antibodies / blood
  • Antibodies / drug effects*
  • Antibodies / immunology
  • Central Nervous System / drug effects
  • Central Nervous System / immunology
  • Central Nervous System / physiopathology
  • Drug Resistance / drug effects
  • Drug Resistance / immunology
  • Glatiramer Acetate
  • Humans
  • Immunologic Factors / pharmacology*
  • Immunologic Factors / therapeutic use
  • Interferon-beta / immunology*
  • Interferon-beta / pharmacology
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / immunology*
  • Multiple Sclerosis, Relapsing-Remitting / physiopathology
  • Peptides / pharmacology*
  • Peptides / therapeutic use
  • Retrospective Studies
  • Secondary Prevention
  • Survival Analysis
  • Time
  • Treatment Outcome

Substances

  • Antibodies
  • Immunologic Factors
  • Peptides
  • Glatiramer Acetate
  • Interferon-beta